CAR NK cell therapy for advanced clear cell kidney cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have clear cell kidney cancer that has spread and cannot be removed with surgery.
- Your cancer must have stopped responding to at least one immunotherapy and one targeted therapy (like Sutent).
- A biopsy of your tumor must show that at least 10% of cancer cells have a protein called CD70.
- You must be 18 or older, weigh at least 88 pounds (40 kg), and be in fairly good health (able to do daily activities).
- You cannot have serious heart, lung, liver, or kidney problems, or an active infection requiring IV antibiotics.
- You must be willing to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
This trial tests an experimental treatment using your own immune cells, modified to attack cancer cells that have a specific marker called CD70. It's for people with advanced clear cell kidney cancer who have already tried standard treatments.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
This trial is testing a new type of cell therapy for advanced kidney cancer that has not responded to standard treatments. The therapy takes your own immune cells, modifies them to target a protein called CD70 on the cancer cells, and gives them back to you to help fight the cancer.
Hear when a new Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.